EA031447B1 - Антитела, которые связываются с sdr белками, и способы их использования - Google Patents

Антитела, которые связываются с sdr белками, и способы их использования Download PDF

Info

Publication number
EA031447B1
EA031447B1 EA201390967A EA201390967A EA031447B1 EA 031447 B1 EA031447 B1 EA 031447B1 EA 201390967 A EA201390967 A EA 201390967A EA 201390967 A EA201390967 A EA 201390967A EA 031447 B1 EA031447 B1 EA 031447B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
sequence
seq
ser
light chain
Prior art date
Application number
EA201390967A
Other languages
English (en)
Russian (ru)
Other versions
EA201390967A1 (ru
Inventor
Тим БОМОН
Марк Ерун КВАККЕНБОС
Эрик Дж. Браун
Джон Хироши Морисаки
Ваутер Л.В. Хазенбос
Санджив Мариатхасан
Кимберли Кадзихара
И Ся
Original Assignee
Аимм Терапьютикс Б.В.
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аимм Терапьютикс Б.В., Дженентек, Инк. filed Critical Аимм Терапьютикс Б.В.
Publication of EA201390967A1 publication Critical patent/EA201390967A1/ru
Publication of EA031447B1 publication Critical patent/EA031447B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
EA201390967A 2009-07-15 2010-07-15 Антитела, которые связываются с sdr белками, и способы их использования EA031447B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558 2009-07-15
PCT/NL2010/050456 WO2011008092A2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Publications (2)

Publication Number Publication Date
EA201390967A1 EA201390967A1 (ru) 2014-01-30
EA031447B1 true EA031447B1 (ru) 2019-01-31

Family

ID=41467048

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390967A EA031447B1 (ru) 2009-07-15 2010-07-15 Антитела, которые связываются с sdr белками, и способы их использования

Country Status (24)

Country Link
US (9) US20110020323A1 (enExample)
EP (1) EP2454284B1 (enExample)
JP (3) JP6192294B2 (enExample)
KR (1) KR101832201B1 (enExample)
CN (2) CN102666583B (enExample)
AR (1) AR077756A1 (enExample)
AU (2) AU2010271582B2 (enExample)
BR (1) BR112012000953A8 (enExample)
CA (1) CA2768204A1 (enExample)
DK (1) DK2454284T3 (enExample)
EA (1) EA031447B1 (enExample)
ES (1) ES2673323T3 (enExample)
HK (1) HK1222418A1 (enExample)
HU (1) HUE038277T2 (enExample)
IL (3) IL217497A (enExample)
MX (1) MX350234B (enExample)
NZ (2) NZ598063A (enExample)
PL (1) PL2454284T3 (enExample)
SG (2) SG177653A1 (enExample)
SI (1) SI2454284T1 (enExample)
TR (1) TR201809128T4 (enExample)
TW (2) TW201610153A (enExample)
WO (1) WO2011008092A2 (enExample)
ZA (2) ZA201200363B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021001906B1 (pt) 2005-12-09 2022-03-29 Kling Biotherapeutics B.V. Método para aumentar a estabilidade de uma célula produtora de anticorpo, método para produzir uma célula produtora de anticorpo que é estável durante pelo menos uma semana, método para produzir linhagem de células b, e método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
ES2666584T3 (es) 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
PT2646466T (pt) 2010-12-02 2017-06-07 Aimm Therapeutics Bv Meios e métodos para produzir anticorpos de alta afinidade
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2890427C (en) 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
US9809645B2 (en) 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US9884126B2 (en) * 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
MX369022B (es) * 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
ES2729057T3 (es) 2013-12-17 2019-10-30 Aimm Therapeutics Bv Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
WO2016090038A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023896A1 (en) * 1995-01-30 1996-08-08 Peter Truog Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus
WO2006034488A2 (en) * 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2008121616A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192175A1 (en) 1994-06-07 1995-12-21 Ambrose Cheung Surface protein of staphylococcus aureus
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6635473B1 (en) 1998-08-31 2003-10-21 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
WO2000012131A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
BR0207068A (pt) 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004025416A2 (en) 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1631581A4 (en) * 2003-05-29 2006-10-18 Inhibitex Inc SDR PROTEINS FROM STAPHYLOCOCCUS CAPITIS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF INFECTIONS
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US8475798B2 (en) 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
AU2007221321B2 (en) 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
HUE031614T2 (en) 2008-01-31 2017-07-28 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Treatment of microbial infections
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023896A1 (en) * 1995-01-30 1996-08-08 Peter Truog Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus
WO2006034488A2 (en) * 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2008121616A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DAVIES, J. RIECHMANN, L.: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY., ELSEVIER SCIENCE PUBLISHERS BV., NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), NL, pages 169 - 179, XP004070292, ISSN: 1380-2933, DOI: 10.1016/S1380-2933(96)00045-0 *
ELLIOTT, T. WASHINGTON, T. LAMBERT, P.: "Antibody response to Staphylococcal slime and lipoteichoic acid", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 360, no. 9349, 14 December 2002 (2002-12-14), AMSTERDAM, NL, pages 1977, XP004795241, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(02)11874-5 *
GAUDREAU, M.C. LACASSE, P. TALBOT, B.G.: "Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 5, 8 December 2006 (2006-12-08), AMSTERDAM, NL, pages 814 - 824, XP005798871, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2006.09.043 *
H.I.WERGELAND ET AL.: "Antibodies to Staphylococcal Peptidoglycan and its Peptide Epitopes, Techoic Acid, and Lipotechoic Acid in Sera from Blood Donors and Patients with Staphylococcal Infections.", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 27., no. 06., 1 June 1989 (1989-06-01), US, pages 1286 - 1291., XP002120750, ISSN: 0095-1137 *
HAMMONDS, S.J. ; EASTERBROOK, T.J. ; MCILLMURRAY, M.B.: "Differentiation of enterococci from other group D streptococci by means of a specific monoclonal antibody", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 82, no. 1, 15 July 1991 (1991-07-15), GB, pages 91 - 94, XP023971357, ISSN: 0378-1097, DOI: 10.1111/j.1574-6968.1991.tb04845.x *
HETHERINGTON SETH, ET AL: "Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 50, no. 10, 1 October 2006 (2006-10-01), US, pages 3499 - 3500, XP002601814, ISSN: 0066-4804, DOI: 10.1128/AAC.00407-06 *
HOLT, L.J. HERRING, C. JESPERS, L.S. WOOLVEN, B.P. TOMLINSON, I.M.: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY., ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), GB, pages 484 - 490, XP004467495, ISSN: 0167-7799, DOI: 10.1016/j.tibtech.2003.08.007 *
JOHN JOSEPH F JR: "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 8, no. 5, 1 October 2006 (2006-10-01), London, GB, pages 455 - 460, XP009138964, ISSN: 1464-8431 *
MCCREA K.W, ET AL: "The serine-aspartate repeat (Sdr) protein family in staphylococcus epidermidis", JOURNAL OF GENERAL MICROBIOLOGY, vol. 146, no. 7, 1 July 2000 (2000-07-01), pages 1535 - 1546, XP002955253, ISSN: 1350-0872 *
REILLEY SANDRA, ET AL: "Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 49, no. 3, 1 March 2005 (2005-03-01), US, pages 959 - 962, XP002601815, ISSN: 0066-4804, DOI: 10.1128/AAC.49.3.959-962.2005 *
SCHAFFER ADAM C ET AL: "Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model.", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 4, 1 April 2006 (2006-04-01), US, pages 2145 - 2153, XP002462561, ISSN: 0019-9567, DOI: 10.1128/IAI.74.4.2145-2153.2006 *
TUCHSCHERR LORENA P N, ET AL: "Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 12, 1 December 2008 (2008-12-01), US, pages 5738 - 5744, XP002601813, ISSN: 0019-9567, DOI: 10.1128/IAI.00874-08 *
YIN RONG-LAN, ET AL: "Construction and immunogenicity of a DNA vaccine containing clumping factor A of Staphylococcus aureus and bovine IL18.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 132, no. 2-4, 15 December 2009 (2009-12-15), Amsterdam, NL, pages 270 - 274, XP002601812, ISSN: 0165-2427, DOI: 10.1016/J.VETIMM.2009.05.012 *

Also Published As

Publication number Publication date
SG177653A1 (en) 2012-02-28
KR101832201B1 (ko) 2018-02-28
US20110020323A1 (en) 2011-01-27
KR20120065326A (ko) 2012-06-20
EP2454284A2 (en) 2012-05-23
IL238074A (en) 2016-06-30
JP2012533293A (ja) 2012-12-27
SG10201704269RA (en) 2017-06-29
WO2011008092A3 (en) 2011-05-26
PL2454284T3 (pl) 2018-09-28
ZA201400644B (en) 2015-10-28
JP2016135771A (ja) 2016-07-28
TW201107470A (en) 2011-03-01
MX350234B (es) 2017-08-30
US9399673B2 (en) 2016-07-26
CN105440133A (zh) 2016-03-30
US9266943B2 (en) 2016-02-23
HK1222418A1 (zh) 2017-06-30
US20130253175A1 (en) 2013-09-26
ZA201200363B (en) 2014-06-25
AR077756A1 (es) 2011-09-21
EA201390967A1 (ru) 2014-01-30
ES2673323T3 (es) 2018-06-21
IL242207A0 (en) 2015-11-30
CA2768204A1 (en) 2011-01-20
AU2010271582A2 (en) 2013-05-16
JP6192294B2 (ja) 2017-09-06
US20130261293A1 (en) 2013-10-03
AU2016250398A1 (en) 2016-11-17
US9927428B2 (en) 2018-03-27
EP2454284B1 (en) 2018-04-11
JP2018134089A (ja) 2018-08-30
NZ616921A (en) 2015-06-26
BR112012000953A2 (pt) 2016-11-22
US20170067880A1 (en) 2017-03-09
US9688745B2 (en) 2017-06-27
AU2010271582B2 (en) 2016-07-28
US20160222096A1 (en) 2016-08-04
CN102666583B (zh) 2015-11-25
NZ598063A (en) 2014-07-25
US8617556B2 (en) 2013-12-31
TWI502068B (zh) 2015-10-01
WO2011008092A2 (en) 2011-01-20
US20150376266A1 (en) 2015-12-31
TW201610153A (zh) 2016-03-16
IL217497A (en) 2015-11-30
US9458228B2 (en) 2016-10-04
TR201809128T4 (tr) 2018-07-23
US20140235828A1 (en) 2014-08-21
US20180292391A1 (en) 2018-10-11
US20160168232A9 (en) 2016-06-16
US20120157665A1 (en) 2012-06-21
DK2454284T3 (en) 2018-07-02
HUE038277T2 (hu) 2018-10-29
WO2011008092A4 (en) 2011-07-07
SI2454284T1 (en) 2018-07-31
AU2016250398B2 (en) 2018-09-27
BR112012000953A8 (pt) 2017-12-26
AU2010271582A1 (en) 2012-03-01
IL217497A0 (en) 2012-02-29
US9090677B2 (en) 2015-07-28
CN102666583A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
AU2016250398B2 (en) Gram-positive bacteria specific binding compounds
AU2016353073A1 (en) Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
JP2024105229A (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
KR20170136637A (ko) 항-스타필로코커스 아우레우스 항체 배합 제제
HK1171238A (en) Gram-positive bacteria specific binding compounds
HK1171238B (en) Gram-positive bacteria specific binding compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU